Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06255704
Other study ID # MCL BTKi immunochemotherapy
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date March 15, 2024
Est. completion date December 1, 2027

Study information

Verified date February 2024
Source Shanxi Province Cancer Hospital
Contact Liping Su, M.D.
Phone 13835158122
Email sulp2005@sohu.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluation the efficacy and safety of Zanubrutinib + R-CHOP/R-DHAP for the treatment mantle cell lymphoma.


Description:

A single-arm, single-center, open-label phase II study of Zanubrutinib combined with R-CHOP/R-DHAP alternating induction therapy followed by Zanubrutinib rituximab maintenance therapy.The primary objective of this study was to assess CR and ORR rates after 6 cycles of initiation (i.e., at the end of induction therapy), and to collect adverse events during induction and maintenance therapy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 23
Est. completion date December 1, 2027
Est. primary completion date January 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Histologically confirmed diagnosis of MCL according to WHO classification; - Previously untreated MCL. - Age = 18 and = 70 years old. - ECOG, 0~2. - Suitable for high-dose treatment including high-dose Ara-C. - Stage II-IV (Ann Arbor). - Measurable disease by computed tomography (CT)/magnetic resonance imaging (MRI). Measurable disease was defined as at least 1 lymph node > 1.5 cm in longest diameter and measurable in 2 perpendicular dimensions; in case of bone marrow infiltration only, bone marrow aspiration and biopsy are mandatory for all staging evaluations. - The following laboratory tests during the screening period (unless related to MCL disease) - 1) Neutrophils =1×109/L within 7 days prior to study entry, and no growth factor support therapy. - 2) Platelets =75×109/L within 7 days prior to study entry without growth factor support or blood transfusion. - 3) Hemoglobin =75g/L shall not be transfused within 7 days before the test. If bone marrow is involved, neutrophils =0.75×109/L, platelets =50×109/L, hemoglobin =50g/L) - 4) Creatinine clearance =30ml/min - 5) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =3× upper limit of normal (ULN). - International Standardized ratio (INR) =1.5 and activated partial prothrombin kinase time (APTT) =1.5×ULN. If there is a clotting factor inhibitor that causes an elevated INR or prolonged APTT, it is up to the investigator to decide whether to enroll the patient. - Sexually active men and women of child-bearing potential must agree to use highly effective contraceptives (eg, condoms, implants, injectables, combined oral contraceptives, intrauterine devices, sexual abstinence, or sterilized partner) while on study; this should be maintained for 90 days after the last dose of study drug - Life expectancy > 3 months. - Written informed consent form according to GCP and national regulations. Exclusion Criteria: - Known CNS involvement of MCL, Leukemic non-lymphonodular mantle cell lymphoma was excluded. - Major surgery within 4 weeks of screening - Concomitant or previous malignancies within the last 2 years other than basal cell skin cancer or in situ uterine cervix cancer - Clinically significant cardiovascular disease such as uncontrolled arrhythmias and hypertension , congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification or LVEF below 50%(AHA,2016) - QTcF > 450 msec or other significant electrocardiogram (ECG) abnormalities including second-degree atrioventricular block Type II, or third-degree atrioventricular block - Clinically significant hypersensitivity (eg, anaphylactic or anaphylactoid reactions to the compound of zanubrutinib itself or to the excipients in its formulation) - Requires treatment with strong CYP3A inhibitors or strong CYP3A inducers - Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction - Active infection including infections requiring oral or intravenous antimicrobial therapy - Patients with unresolved hepatitis B or C infection or known HIV positive infection - History of stroke or intracranial hemorrhage within 6 months before first dose of study drug - Pregnancy or lactation - Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could have compromised the patient's safety, or put the study at risk - Participation in another clinical trial within 30 days before enrollment in this study - poor compliance

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Zanubrutinib and RCHOP/RDHAP
Alternating 3× R-CHOP/ 3× R-DHAOx, every 21 days plus oral Zanubrutinib in cycle 1, 3, 5 in combination with R-CHOP: R-CHOP (cycle 1,3,5): Rituximab 375 mg/m2 D1, I.V. Cyclophosphamide 750 mg/m2 D1, I.V. Doxorubicine 50 mg/m2 D1, I.V. Vincristine 1.4mg/m2(max 2mg)D1, I.V. Prednisone 100mg D1-5, oral Zanubrutinib 160mg BID D1-21, oral R-DHAP(cycle 2,4,6): Dexamethasone 40mg D1-4 oral/I.V. Rituximab 375mg/m2 D1, I.V. Ara-C 2×2g/m2 q12h D2, I.V. Cisplatin 100mg/m2 D1, I.V. Maintenance: Zanubrutinib, 160mg PO BID, rituximab 375mg/m2 repeated every 8 weeks, treatment will continue for up to 2 years or until progressive disease?

Locations

Country Name City State
China Hematology Department of ShanXi Cancer Hospital Taiyuan Shanxi

Sponsors (1)

Lead Sponsor Collaborator
Shanxi Province Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary CR rate after 6 cycles of induction therapy To evaluate the CR rate after Zanubrutinib-based induction therapy in subjects with newly diagnosed MCL. 18 weeks
Secondary ORR rate after 6 cycles of induction therapy To evaluate the ORR rate after Zanubrutinib-based induction therapy in subjects with newly diagnosed MCL. 18 weeks
Secondary Progression free survival (PFS) The time from start of treatment to progression or death from any cause 60 weeks
Secondary Overall survival (OS) The time from start of treatment to death from any cause 60 weeks
Secondary duration of response, DOR Defined as the time after the start of treatment from the first time remission criteria are met until disease progression or death is objectively recorded, whichever occurs first. 60 weeks
Secondary MRD negative rate at the end of induction therapy MRD negative rate in peripheral blood or bone marrow at the end of induction therapy 18 weeks
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Recruiting NCT05976763 - Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma Phase 3
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Recruiting NCT05365659 - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas Phase 1
Recruiting NCT05471843 - Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma Phase 1/Phase 2
Recruiting NCT05076097 - A Study of OLR in First-line Treatment of Mantle Cell Lymphoma Phase 2
Active, not recruiting NCT04082936 - A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma Phase 1/Phase 2
Active, not recruiting NCT03891355 - Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL Phase 2
Recruiting NCT04883437 - Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas Phase 2
Terminated NCT03585725 - A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma Early Phase 1
Recruiting NCT02892695 - PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma Phase 1/Phase 2
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Completed NCT01665768 - Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma Phase 2
Completed NCT01437709 - Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant Phase 2
Completed NCT00963534 - Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. Phase 1/Phase 2
Completed NCT00921414 - Mantel Cell Lymphoma Efficacy of Rituximab Maintenance Phase 3
Withdrawn NCT00541424 - Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma N/A
Completed NCT01456351 - Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab Phase 3
Completed NCT01851551 - Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL Phase 1/Phase 2
Completed NCT03295240 - The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma Early Phase 1